Summary:
In this podcast, recorded at the February 2024 IO360º summit, a panel of biopharma, finance and investment experts discuss the fundability features of IO biotechs, and the current pharma needs that will drive potential partnerships or M&A.
For more information, go to IO360summit.com.
Moderators
Emmett Schmidt, MD, PhD
VP, Clinical Oncology and Lead, External Collaborations
Merck
Irina Margine, PhD
Principal, Biotech Private Equity
Wellington Management
Khalil Barrage
Managing Partner
Invus Group
Jeffrey M. Bockman, PhD
Expert Advisor and EVP, Oncology
Lumanity
Gayatri Varma, PhD
Executive Director and Head of Transactions, Oncology R&D
AstraZeneca
Speakers
Axel Hoos, MD, PhD
Former CEO
Scorpion Therapeutics
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.